» Articles » PMID: 33015162

Arctigenin Inhibits Glioblastoma Proliferation Through the AKT/mTOR Pathway and Induces Autophagy

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2020 Oct 5
PMID 33015162
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Arctigenin (ARG) is a natural lignan compound extracted from Arctium lappa and has displayed anticancer function and therapeutic effect in a variety of cancers. Arctigenin is mainly from Arctium lappa extract. It has been shown to induce autophagy in various cancers. However, as for whether arctigenin induces autophagy in gliomas or not, the specific mechanism is still worth exploring.

Methods: Using CCK8, the monoclonal experiment was made to detect the proliferation ability. The scratch experiment and the transwell experiment were applied to the migration and invasion ability. PI/RNase and FITC-conjugated anti-annexin V were used to detect the cell cycle and apoptosis. Western blotting was used to determine the specified protein level, and constructed LC3B-GFP plasmid was used for analysis of autophagy.

Results: Our research showed that ARG inhibited the growth and proliferation and invasion and migration of glioma cells in a dose-dependent manner (U87MG and T98G) and arrested the cell cycle and induced apoptosis. Interestingly, ARG induced autophagy in a dose-dependent manner. We applied Western blotting to measure the increase in the key autophagy protein LC3B, as well as some other autophagy-related proteins (increase in Beclin-1 and decrease in P62). In order to further explore the mechanism that ARG passed initiating autophagy to inhibit cell growth, we further found by Western blotting that AKT and mTOR phosphorylation proteins (P-AKT, P-mTOR) were reduced after ARG treatment, and we used AKT agonists to rescue, and the phosphorylated proteins of AKT and mTOR increased, and we found that the autophagy-related proteins were also reversed. And interestingly, the protein of apoptosis was also reversed along with autophagy.

Conclusions: We thought ARG inhibited the proliferation of glioma cells by inducing autophagy and apoptosis through the AKT/mTOR pathway.

Citing Articles

GRP78 in Glioma Progression and Therapy: Implications for Targeted Approaches.

Yang Y, Li W, Zhao Y, Sun M, Xing F, Yang J Biomedicines. 2025; 13(2).

PMID: 40002794 PMC: 11852679. DOI: 10.3390/biomedicines13020382.


Adiponectin facilitates the cell cycle, inhibits cell apoptosis and induces temozolomide resistance in glioblastoma via the Akt/mTOR pathway.

Sun P, Liu F, Huo K, Wang J, Cheng Y, Shang S Oncol Lett. 2025; 29(3):127.

PMID: 39807099 PMC: 11726000. DOI: 10.3892/ol.2025.14875.


Arctigenin inhibits the progression of colorectal cancer through epithelial-mesenchymal transition via PI3K/Akt/mTOR signaling pathway.

Chen X, Liu P, Sheng N, Li X, Hu R, Zhu L PLoS One. 2024; 19(9):e0308947.

PMID: 39331595 PMC: 11432899. DOI: 10.1371/journal.pone.0308947.


dECM restores macrophage immune homeostasis and alleviates iron overload to promote DTPI healing.

Zhang J, Si R, Gao Y, Shan H, Su Q, Feng Z Regen Biomater. 2024; 11:rbad118.

PMID: 38404617 PMC: 10884736. DOI: 10.1093/rb/rbad118.


Regulated cell death in glioma: promising targets for natural small-molecule compounds.

Han M, Li S, Fan H, An J, Peng C, Peng F Front Oncol. 2024; 14:1273841.

PMID: 38304870 PMC: 10830839. DOI: 10.3389/fonc.2024.1273841.


References
1.
Polivka Jr J, Janku F . Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 2013; 142(2):164-75. DOI: 10.1016/j.pharmthera.2013.12.004. View

2.
Feng F, Zhang M, Yang C, Heng X, Wu X . The dual roles of autophagy in gliomagenesis and clinical therapy strategies based on autophagic regulation mechanisms. Biomed Pharmacother. 2019; 120:109441. DOI: 10.1016/j.biopha.2019.109441. View

3.
Shen Y, Liu Y, Li B, Liu T, Wang G . Evaluation on antiviral activity of a novel arctigenin derivative against multiple rhabdoviruses in aquaculture. Virus Res. 2020; 285:198019. DOI: 10.1016/j.virusres.2020.198019. View

4.
He Y, Fan Q, Cai T, Huang W, Xie X, Wen Y . Molecular mechanisms of the action of Arctigenin in cancer. Biomed Pharmacother. 2018; 108:403-407. DOI: 10.1016/j.biopha.2018.08.158. View

5.
LAUPER N, Beck A, Cariou S, Richman L, Hofmann K, Reith W . Cyclin E2: a novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle. Oncogene. 1998; 17(20):2637-43. DOI: 10.1038/sj.onc.1202477. View